NRG-GY005: Ovarian, fallopian tube, or primary peritoneal cancer - Clinical Trial
What is the Purpose of this Study?
Who Can Participate in the Study?
Adult women who have recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer.
What is Involved?
If you choose to join this study you will:
- Be randomized (like a flipping a coin) into one of the following groups::
-- Group 1: receive standard chemotherapy
-- Group 2: receive a combination of the study drugs cediranib and olaparib
- Have blood drawn
- Get a CT scan every two months
-Group 2 participants will also:
-- Have a urine test
-- Have an ECG (to measure the activity of the heartbeat)
-- Take their blood pressure twice a day and record it
-- Complete follow-up phone calls once a week for 12 weeks